Schizophrenia and Depression: Comorbidity and Differential Diagnosis
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Depression commonly accompanies schizophrenia, yet the relationship can be difficult to recognize accurately. Someone living with schizophrenia may experience a distinct major depressive episode, subthreshold depressive symptoms, low motivation related to negative symptoms, distress associated with psychosis, medication adverse effects, or several of these simultaneously. Some of these conditions look similar from the outside while requiring different assessment and treatment decisions. The central question is how clinicians identify depression when schizophrenia is already present and how they distinguish it from other psychiatric presentations.
The clinical significance is considerable. A systematic review and meta-analysis of 18 studies involving 6,140 stabilized outpatients with schizophrenia estimated the prevalence of comorbid major depressive disorder at 32.6%, with substantial variation across studies. This estimate describes particular study populations and cannot diagnose an individual. Etchecopar-Etchart and colleagues, 2021. The National Institute for Health and Care Excellence (NICE) recommends monitoring for depression throughout psychosis and schizophrenia care.
This guide examines prevalence, symptoms, clinical differential diagnosis, negative symptoms, schizoaffective disorder, psychotic depression, first-episode psychosis, treatment evidence, suicide risk, functional recovery, and practical steps for patients and supporters. It provides clinical education and a framework for informed conversations with professionals rather than an individual diagnosis.
I. What Does Schizophrenia With Depression Mean?
Schizophrenia is a psychiatric disorder characterized by a constellation of psychotic and other symptoms, including possible delusions, hallucinations, disorganized thought or behavior, negative symptoms, and cognitive difficulties. The pattern must meet diagnostic criteria and be evaluated over time. Psychosis itself is a clinical syndrome that occurs in several conditions; it is not synonymous with schizophrenia. A hallucination is a perception-like experience without a corresponding external stimulus, while a delusion is a strongly held belief that is not adequately explained by the person's social or cultural context and persists despite meaningful contrary evidence. Neither symptom alone establishes a disorder. NIMH: Schizophrenia; NIMH: Understanding Psychosis.
The word depression is used in several ways. Sadness is an emotion. Depressive symptoms include low mood, loss of pleasure, hopelessness, guilt, diminished energy, changes in sleep and appetite, impaired concentration, and sometimes thoughts of death. A major depressive episode is a defined pattern of symptoms of sufficient duration, severity, and clinical significance. Major depressive disorder is a diagnosis requiring assessment of the person's broader clinical history and exclusion of relevant alternative explanations. A person can need help for depression even when symptoms fall below the diagnostic threshold for a major depressive episode.
In someone with established schizophrenia, clinicians may identify a co-occurring depressive episode or significant depressive symptoms associated with the primary psychotic illness. They also consider whether the symptoms could be explained by negative symptoms, medication effects, a different mood-related diagnosis, medical illness, or distress and loss associated with a difficult period of life. These possibilities may overlap.
Depression has been documented before, during, and after psychotic episodes. It can occur while hallucinations or delusions remain active and during periods when psychosis has largely improved. The chronology challenges the assumption that depression in schizophrenia is invariably a psychological reaction to receiving a diagnosis. Upthegrove, Marwaha, and Birchwood, 2017.
II. How Common Is Depression in Schizophrenia?
Prevalence estimates depend on the definition of depression, the illness stage, sampling method, treatment setting, assessment instrument, and diagnostic system. Rates for any depressive symptoms will differ from rates for a formal diagnosis of major depressive disorder. People receiving care after first-episode psychosis also differ from stabilized outpatients or people with chronic complex needs.
The Etchecopar-Etchart and colleagues meta-analysis reported a pooled estimate of 32.6% for major depressive disorder among stabilized outpatients with schizophrenia, with a 95% confidence interval of 27.9%–37.6%. Between-study heterogeneity was high (I² = 92.6%). The confidence interval reflects statistical uncertainty in the pooled estimate; high heterogeneity additionally means that clinical populations and study conditions do not share one uniform rate.
Depression matters regardless of which population statistic appears in a research summary. Low mood and loss of enjoyment can interfere with relationships, education, work, self-care, engagement with services, and an individual's sense of hope. Clinicians should therefore review mood and suicide risk directly rather than use the severity of psychosis as a proxy for the person's overall wellbeing. NICE CG178.
III. Depression Versus Negative Symptoms of Schizophrenia
1. Why the presentations overlap
Negative symptoms of schizophrenia are reductions in capacities such as emotional expression, motivation, spontaneous speech, social engagement, and initiation of goal-directed behavior. A person may speak very little, stop initiating enjoyable activities, avoid gatherings, or show a restricted outward emotional response. Depression can also lead to reduced activity, social withdrawal, low motivation, diminished pleasure, slowed speech, and fatigue. This creates genuine difficulty in observational diagnosis.
A systematic review by Krynicki and colleagues found that subjective low mood, pessimism, and suicidal thoughts are more useful indicators of depression, while alogia (reduced speech) and blunted affect tend to be more characteristic of negative symptoms. Avolition, anhedonia, reduced energy, and withdrawal may occur in either syndrome. The distinctions are clinical clues, not mechanical rules.
2. Ask about the person's internal experience
An individual experiencing depression may describe painful sadness, hopelessness, excessive guilt, feelings of worthlessness, or a change from previously enjoyed activities. Someone with prominent negative symptoms may have difficulty initiating activity or expressing emotion without sustained sadness or depressive beliefs. Both conditions can coexist, making it important to explore the person's experience in their own words.
Blunted affect refers to outward emotional expression, not proof that emotions are absent. Similarly, silence does not establish lack of interest. A quiet person may be distracted by voices, afraid of judgment, depressed, sedated, experiencing medication-related movement problems, or struggling with primary negative symptoms. The same behavior can arise through multiple mechanisms.
3. Primary and secondary negative symptoms
Primary negative symptoms are considered part of schizophrenia's psychopathology. Secondary negative symptoms may be associated with depression, active delusions or hallucinations, anxiety, social deprivation, untreated medical conditions, or medication effects. Distinguishing them prevents treatable contributors from being overlooked.
For example, a person who becomes lethargic after a substantial medication change needs evaluation for sedation or extrapyramidal adverse effects. Someone who withdraws because persecutory beliefs make social situations frightening needs evaluation of psychotic distress. Someone who reports persistent sadness, loss of pleasure, and hopelessness needs direct depression assessment. Several contributors may be present together. Clinical reviews of negative symptoms emphasize systematically checking for secondary causes. Mosolov and Yaltonskaya, 2022.
4. Negative symptoms, depression, and cognition
Concentration difficulties and poor day-to-day performance also have multiple causes. Cognitive impairment associated with schizophrenia can affect attention, memory, and executive functions; depression can reduce concentration and processing efficiency; sedative medications and sleep problems may further impair performance. The presence of cognitive difficulties alone cannot distinguish schizophrenia-related impairment from a depressive episode.
Clinicians integrate symptom interviews, behavioral observations, medication history, cognitive and functional assessment when indicated, and changes over time. Improvement in one domain does not prove that all other domains share the same mechanism.
IV. Schizophrenia, Schizoaffective Disorder, and Psychotic Depression
1. The essential role of chronology
The core diagnostic questions concern when psychotic symptoms were present, when full mood episodes occurred, how long they lasted, and whether psychotic symptoms continued during periods without a major mood episode. One appointment during which a patient is depressed and hearing voices cannot reconstruct the full course. Clinicians obtain a timeline through interviews, records of previous episodes, and collateral history when appropriate and consented to.
The DSM-5-TR and ICD-11 provide professional diagnostic classifications, but they differ in certain conceptual and temporal requirements. Any description of diagnostic rules should therefore identify the framework being used rather than treating the systems as identical.
2. Schizophrenia with depressive symptoms
Within the DSM framework, schizophrenia may be diagnosed when its criteria are satisfied and full mood episodes, if present, occupy only a minority of the total active and residual duration of illness. The person can simultaneously have significant depressive symptoms or a clinically important major depressive episode that deserves treatment. Depression does not automatically change the underlying diagnosis to schizoaffective disorder.
Clinical judgment also considers the effects of psychosis, medication, substance exposure, and medical illness. A long-standing schizophrenia diagnosis should still be reviewed when reliable new information suggests that the original course was misunderstood.
3. Schizoaffective disorder, depressive type
For DSM-5-TR schizoaffective disorder, a major mood episode occurs during illness meeting the active symptom criterion for schizophrenia; there is also a period of at least two weeks of delusions or hallucinations without a major mood episode; and full mood episodes are present for the majority of the overall active and residual illness duration. Depressive type refers to an illness course in which the relevant mood episodes are major depressive episodes rather than manic episodes.
The majority-versus-minority relationship across the total illness course is critical. ICD-11 uses a more episode-oriented formulation, so this DSM-specific rule should not be assumed to define ICD-11 schizoaffective disorder. These distinctions require a professional longitudinal evaluation. Schizoaffective disorder is an established clinical diagnosis rather than a symptom severity level.
4. Major depressive disorder with psychotic features
In psychotic depression, delusions or hallucinations occur in the context of a major depressive episode. For unipolar major depressive disorder with psychotic features, psychosis is linked to the depressive episode rather than occurring as an independently persistent psychotic illness. A history of psychosis outside major mood episodes prompts consideration of other diagnoses. Psychotic depression is covered separately in our Psychotic Depression: Symptoms, Diagnosis, and Treatment article, the EN-01 canonical owner of that condition.
Psychotic content can include themes of guilt, worthlessness, bodily disease, persecution, or other beliefs. Whether delusional content appears mood-congruent or mood-incongruent is relevant but does not substitute for assessing episode timing and formal diagnostic criteria.
5. Bipolar disorder with psychotic features
Mania or hypomania in a person's lifetime can substantially change the differential diagnosis. In bipolar disorder, psychotic symptoms may occur during severe mood episodes. A manic episode is characterized by a sustained abnormal change in mood and increased energy or activity, together with other symptoms such as decreased need for sleep, heightened activity, grandiosity, or pressured speech, with clinically significant consequences. One night of poor sleep or speech disturbance does not establish mania.
Bipolar-specific psychosis has a distinct canonical owner in the English Hub. Here it matters because identifying a manic or hypomanic history affects diagnostic formulation and can influence the safety of antidepressant prescribing.
6. Medical, medication-related, and substance-associated causes
Symptoms that resemble psychosis or depression can occur with delirium, neurological illness, endocrine disturbance, intoxication, withdrawal, medication effects, or neurocognitive disorders. Sudden fluctuating attention, disorientation, fever, seizures, prominent neurological abnormalities, or an abrupt change in consciousness warrant urgent medical assessment. NIMH: Understanding Psychosis identifies multiple possible causes of psychotic symptoms.
Clinical assessment also considers schizophreniform disorder, brief psychotic disorder, delusional disorder, substance-induced psychosis, and psychosis due to another medical condition when the presentation fits. Each possibility is judged using the duration, phenomenology, context, and relevant exclusion criteria; a hallucination or depressed mood alone does not decide among them.
V. Depression Before, During, and After First-Episode Psychosis
A first episode of psychosis can involve fear, loss of sleep, disruption to school or employment, family strain, stigmatizing experiences, and uncertainty about the future. Depression may have begun before the episode, be present during acute illness, or emerge in recovery. These are different possible trajectories, and they can be shaped by both illness-related and psychosocial factors.
Early intervention should assess depressive experiences rather than wait until hallucinations and delusions are controlled. The APA schizophrenia practice guideline recommends coordinated specialty care for first-episode psychosis, combining pharmacotherapy when indicated with psychological interventions, case management, family involvement, and educational or vocational support. NICE CG178 similarly promotes early specialist treatment and monitoring for coexisting conditions.
A person who reports fewer voices but says life has no meaning still requires attentive assessment. The effectiveness of psychosis treatment cannot be measured solely by changes in positive symptoms. Depressive distress, cognition, physical health, quality of life, social opportunity, and personal recovery goals remain independently important.
VI. How Depression Is Assessed in Schizophrenia
1. A careful interview across time
A clinician asks about the onset, persistence, severity, and functional impact of sadness, loss of pleasure, guilt, worthlessness, hopelessness, sleep and appetite change, psychomotor symptoms, concentration difficulty, and thoughts of suicide. Important contextual questions include whether mood changed before or after psychosis, whether medication doses changed, whether a medical illness developed, and whether previous episodes included mania or hypomania.
Psychotic symptoms are assessed separately: hallucinations, delusions, degree of conviction, distress, behavior, and safety consequences. The clinician examines negative symptoms and cognitive and daily-living difficulties as their own domains. This multidimensional formulation is consistent with NICE CG178.
2. The Calgary Depression Scale for Schizophrenia
The Calgary Depression Scale for Schizophrenia (CDSS) is a clinician-administered, nine-item scale developed to assess depression while reducing confusion with negative and medication-related movement symptoms. Foundational validation studies examined reliability, validity, and specificity for depressive symptoms in people with schizophrenia. Addington, Addington, and Maticka-Tyndale, 1992; Addington and colleagues, 1994.
A rating scale quantifies selected symptoms and may help monitor change; it is not a stand-alone diagnosis. A CDSS score cannot establish schizophrenia, major depressive disorder, or schizoaffective disorder. General depression scales may be useful as supplementary measures, but sleep disturbance, fatigue, poor concentration, and reduced activity may have multiple explanations in people experiencing psychosis.
3. Medication and medical review
Sedation, medication-induced parkinsonism, akathisia, disturbed sleep, thyroid disease, anemia, chronic pain, substance use, and other conditions can influence mood and functioning. An examination and appropriate targeted investigations may help distinguish them. Routine testing should be chosen by a clinician based on history, physical findings, medications, and risk rather than ordered from an online checklist.
Some adverse effects produce strikingly different experiences: akathisia involves distressing internal restlessness; sedation makes it difficult to stay alert; parkinsonism can slow movement and diminish facial expression. Each may be mistaken for or may coexist with depression. Discuss side effects and changes in functioning with the prescribing clinician before making treatment changes.
4. Functioning, relationships, and the person's goals
Assessment also asks what the person wishes to do and which obstacles matter most. Someone may want to return to study, develop friendships, care for family, or manage daily routines. Depression, negative symptoms, medication effects, and limited social opportunities can restrict these activities through different pathways. Functional evaluation reveals needs that symptom scores alone may miss.
VII. Depression and Suicide Risk in Schizophrenia
Depressive symptoms, hopelessness, past suicidal behavior, distressing psychotic experiences, agitation, substance use, recent losses, and disrupted continuity of care can be relevant to an individual's suicide-risk assessment. No population association can predict an individual outcome. Clinicians assess the person's immediate thoughts, plans, intentions, access to means, prior attempts, strengths, available support, and changing clinical circumstances rather than relying on a diagnosis or score alone.
If a person expresses an intention to end their life, has made preparations, cannot maintain basic safety, is severely disoriented, or experiences another acute emergency, contact local emergency services or a qualified crisis team promptly. In the United States, calling or texting 988 reaches the Suicide & Crisis Lifeline. Clinical professionals can develop an individualized safety and follow-up plan; online information cannot perform an emergency assessment.
It is appropriate to ask directly and calmly about suicidal thoughts when someone expresses hopelessness or a wish to die. Take the answer seriously without assuming every depressed thought reflects a delusion. Family members and caregivers should know how to contact the treating service and how to obtain urgent help when safety changes.
VIII. Evidence-Based Treatment When Schizophrenia and Depression Co-Occur
1. Treatment follows the formulation
Treatment depends on which conditions are actually present. Active psychosis, a major depressive episode, medication-related symptoms, prominent negative symptoms, sleep disturbance, bipolar illness, and medical causes require different clinical responses. A combination may be present, so treatment often addresses several domains at once. Shared decision-making considers symptom relief, functioning, adverse effects, relapse prevention, and the person's values.
Antipsychotic medication is an established component of schizophrenia treatment. The APA guideline recommends medication treatment and individualized monitoring. NICE CG178 recommends discussing benefits and harms, baseline health, and metabolic, neurological, cardiovascular, and other treatment-related effects. Antipsychotics cannot be assumed to treat all depressive experiences simply because psychotic symptoms improve.
2. Antidepressants: benefits and limitations
Antidepressants may be considered as an adjunct when clinically significant depressive symptoms persist, depending on diagnostic assessment, previous treatment response, drug interactions, side effects, and bipolar history. A 2016 systematic review and meta-analysis of 82 trials found a small average improvement in depressive symptoms from adding antidepressants to antipsychotics. Trials varied in drugs, target outcomes, and participant characteristics, so the average result does not predict an individual response.
The evidence remains mixed. A separate meta-analysis of 42 double-blind studies did not find a statistically significant pooled improvement in depressive symptoms under its analyses, while a Cochrane review identified important limitations in the small trials specifically targeting concurrent schizophrenia and depression. The reviews ask overlapping but not identical questions and should not be presented as a universal treatment rule.
No particular antidepressant, dose, combination, or discontinuation schedule follows from these findings. Medication decisions require professional review of possible interactions, adverse effects, cardiovascular risks, sedation, anticholinergic burden, potential for mood switching when bipolar illness is present, and patient preferences. Do not abruptly stop or alter prescribed medication without discussing the risks and a plan with the treating clinician.
3. Psychotherapy and psychosocial intervention
Cognitive behavioral therapy for psychosis (CBTp), family intervention, supported education and employment, skills support, and recovery-oriented care may be appropriate components of schizophrenia treatment. Depression-specific psychological support can address hopelessness, shame, withdrawal, anxiety, grief, loss of opportunities, and disrupted daily routines. The quantity and directness of evidence for a specific intervention in people with both schizophrenia and diagnosed major depression differ across approaches. APA schizophrenia guideline; NICE CG178.
Psychotherapy may be adapted to cognitive challenges, symptom severity, communication needs, and what the person finds acceptable. A treatment plan can include rehabilitation, housing assistance, social connection, activity scheduling, physical health care, and support for goals meaningful to the person. These practical elements may make psychological and medication treatment easier to access and sustain.
4. Clozapine and suicide-risk reduction
Clozapine has specialized indications for schizophrenia, including treatment-resistant illness and ongoing substantial risk of suicide despite other treatment. The APA guideline recommends clozapine in these situations. Clozapine is not a routine antidepressant or an automatic response to low mood. The medication requires specialist prescribing and monitoring because serious adverse effects can occur.
A 2025 U.S. FDA safety communication reports the removal of the U.S. clozapine REMS program effective June 13, 2025. The change in administrative requirements did not remove the clinical importance of absolute neutrophil count monitoring or of evaluating the medication's broader safety profile.
5. Ongoing review and recovery-oriented care
Clinicians reassess depressive symptoms, psychosis, adverse effects, physical health, cognition, relationships, and daily functioning at successive stages of care. NICE NG181 addresses rehabilitation and monitoring of coexisting mental and physical health conditions in complex psychosis.
Goals evolve over time. Some people prioritize relief from distress; others prioritize study, friendships, work, independent living, or improved energy and concentration. Recognizing depression as a legitimate clinical target helps ensure that treatment addresses the person's quality of life as well as positive psychotic symptoms.
IX. Practical Guidance for Patients, Families, and Supporters
A useful appointment summary records when mood changed, whether sadness or loss of enjoyment is present, how sleep and appetite have shifted, whether psychotic symptoms have changed, and whether the onset followed a medication adjustment or major stressor. Write down concrete examples: I stopped enjoying music three weeks ago; I feel slowed down since my prescription changed; I wake early and feel hopeless; or I still hear voices but my mood has improved. These descriptions help differentiate potential causes.
Ask the care team what diagnosis or working formulation is being considered, which symptoms the current treatment targets, when benefits and side effects will be reviewed, whether a validated depression assessment would be useful, and how to seek help if mood worsens. For complex presentations, request clarification about the timeline connecting mood and psychosis.
Supporters can listen, avoid stigmatizing explanations such as laziness or lack of willpower, and ask what practical help the person actually wants. With consent, they can share observations about meaningful changes in mood, sleep, medication effects, and functioning. When someone reports a frightening psychotic experience, acknowledge the distress without confirming an implausible belief as fact. When someone expresses despair, take the emotional suffering seriously in its own right.
X. Prognosis, Functioning, and Quality of Life
The co-occurrence of schizophrenia and depression may be associated with additional distress and impairment, but prognosis is individual. Severity, symptom changes, social opportunities, medical comorbidity, access to support, treatment tolerability, and personal goals all influence outcomes. The presence of depression today cannot determine a person's future independence, family life, or ability to work or study.
Recovery may involve sustained remission for some symptoms, improved management of others, meaningful relationships, stronger self-determination, and participation in valued activities. The World Health Organization emphasizes the importance of effective treatment, psychosocial support, rights, and community participation. The quality of care is judged partly by whether it responds to the person's own priorities.
XI. Frequently Asked Questions
1. Can schizophrenia and major depression occur together?
Yes. Clinicians may diagnose a co-occurring depressive episode in someone with schizophrenia when appropriate criteria are met. They must assess negative symptoms, medical causes, medications, mood history, and the relationship of psychosis to mood over time.
2. Does feeling depressed mean schizophrenia is worsening?
Depressed mood can arise for multiple reasons and does not by itself establish psychotic relapse. A change in mood deserves assessment, especially when accompanied by hopelessness, major functional decline, or thoughts of death.
3. Are negative symptoms the same as depression?
No. They can look similar, and they sometimes coexist. Persistent sadness, pessimism, and suicidal thoughts favor a depressive interpretation, whereas reduced speech and restricted emotional expression more strongly suggest negative symptoms. A clinical assessment is still needed. Krynicki et al..
4. Is schizoaffective disorder just schizophrenia with depression?
Schizoaffective disorder is a distinct diagnosis requiring a specific longitudinal relationship between psychotic symptoms and full mood episodes. The presence of both symptom types at one visit does not establish that diagnosis.
5. How does psychotic depression differ from schizophrenia with depression?
The central distinction concerns the diagnostic context and timing of psychosis relative to mood episodes. For unipolar psychotic depression, psychosis is associated with major depressive episodes. In schizophrenia, psychotic illness can persist outside episodes of depression.
6. Can depression appear after hallucinations improve?
Yes. Mood symptoms can develop or continue during recovery from psychosis. Psychosis and depression should be monitored separately.
7. Can antipsychotics cause symptoms that look like depression?
Some adverse effects—such as sedation, motor slowing, or intense restlessness—can resemble or exacerbate distress and reduced activity. A prescriber can evaluate these possibilities and modify care when appropriate.
8. Are antidepressants safe and effective for everyone with schizophrenia?
No universal response or safety profile exists. Trial evidence is mixed, and individual decisions depend on diagnostic formulation, interactions, adverse effects, and careful monitoring. Helfer et al., 2016.
9. Can a depression questionnaire make this diagnosis?
No. Measures such as the Calgary Depression Scale for Schizophrenia support evaluation and monitoring but do not replace a clinical interview, longitudinal history, and differential diagnosis.
10. When is urgent medical or psychiatric evaluation appropriate?
Seek urgent assistance for immediate suicidal intention, severe disorientation, abrupt confusion, inability to meet essential safety needs, or acute medical symptoms. Other significant new depressive or psychotic symptoms should prompt timely professional assessment.
XII. Clinical Summary
Depression is an important and potentially treatable problem throughout schizophrenia care. Accurate evaluation distinguishes emotional symptoms from negative symptoms, medication effects, and other clinical disorders, while recognizing that more than one can occur simultaneously. A longitudinal account of mood and psychosis is essential when differentiating schizophrenia with depression, schizoaffective disorder, and psychotic depression.
Effective care combines evidence-based treatment of schizophrenia with direct assessment of depressive suffering, physical health, suicidality, adverse effects, and the person's recovery goals. Every symptom change has a clinical context. Shared decisions and repeated reassessment provide a stronger basis for treatment than a diagnosis inferred from an isolated behavior or questionnaire score.
Related Articles
References
Addington, D., Addington, J., Maticka-Tyndale, E., & Joyce, J. (1992). Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research. DOI.
Addington, D., Addington, J., & Maticka-Tyndale, E. (1994). Specificity of the Calgary Depression Scale for schizophrenics. Schizophrenia Research. DOI.
American Psychiatric Association. (2020). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry. DOI.
Etchecopar-Etchart, D., et al. (2021). Comorbid major depressive disorder in schizophrenia: A systematic review and meta-analysis. Schizophrenia Bulletin. DOI.
Galling, B., et al. (2018). Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatrica Scandinavica, 137, 187–205. DOI.
Helfer, B., et al. (2016). Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: A systematic review and meta-analysis. American Journal of Psychiatry. DOI.
Krynicki, C. R., Upthegrove, R., Deakin, J. F. W., & Barnes, T. R. E. (2018). The relationship between negative symptoms and depression in schizophrenia: A systematic review. Acta Psychiatrica Scandinavica. DOI.
Mosolov, S. N., & Yaltonskaya, P. A. (2022). Primary and secondary negative symptoms in schizophrenia. Frontiers in Psychiatry. DOI.
National Institute for Health and Care Excellence. (2014). Psychosis and schizophrenia in adults: Prevention and management (CG178). Recommendations.
National Institute for Health and Care Excellence. (2020). Rehabilitation for adults with complex psychosis (NG181). Recommendations.
National Institute of Mental Health. (n.d.). Schizophrenia. Official publication.
National Institute of Mental Health. (n.d.). Understanding psychosis. Official publication.
Upthegrove, R., Marwaha, S., & Birchwood, M. (2017). Depression and schizophrenia: Cause, consequence, or trans-diagnostic issue? Schizophrenia Bulletin. DOI.
U.S. Food and Drug Administration. (2025). FDA removes the REMS program for the antipsychotic drug clozapine. Official safety communication.
Whitehead, C., Moss, S., Cardno, A., Lewis, G., & Furtado, V. A. (2002). Antidepressants for people with both schizophrenia and depression. Cochrane Database of Systematic Reviews, CD002305. Cochrane review.
World Health Organization. (2025). Schizophrenia. Fact sheet.